Grantham, Mayo, Van Otterloo & Co (GMO)
GNMK

Grantham, Mayo, Van Otterloo & Co (GMO)’s GenMark Diagnostics, Inc GNMK Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-25,600
Closed -$364K – 912
2020
Q3 		$364K Buy
+25,600
New +$391K ﹤0.01% 672

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s GNMK Position: Q4 2020 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2020, closing a stake of 25,600 shares — an estimated $364K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in GNMK in Q3 2020 and held it in 1 quarter. The position peaked at $364K in Q3 2020. 151 funds tracked by Wall St. Rank hold GNMK as of Q4 2020.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining GenMark Diagnostics, Inc position as of Q4 2020 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 25,600 GenMark Diagnostics, Inc shares in Q4 2020, an estimated $364K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in GenMark Diagnostics, Inc in Q3 2020 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s GenMark Diagnostics, Inc position peaked at $364K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2020.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q4 2020, filed 12 Feb 2021.